BDC Healthcare Venture
VC Fund
Montréal, Canada
BDC Healthcare Venture is a venture capital firm specializes in healthcare investments. The firm prefers to invest in the innovative therapeutics, medical technology, health technology, prevention, diagnostics, personalized treatment, mobile technologies and services, robotics, automation and disease management sectors.
- Total investments:
- 18
- Last investment:
- Lead investor:
- 28%
- Fund size:
- $278M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries BDC Healthcare Venture invests in
Stages BDC Healthcare Venture invests in
Countries BDC Healthcare Venture invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 6 contacts → | |||
Round size
- Series A
- $4.2M–$68M
- Series B
- $4.7M–$30M
- Venture - Series Unknown
- $23M–$60M
Investment Focus
Industry
- Health Care 10 (56%)
- Biotechnology 8 (44%)
- Medical Device 6 (33%)
- Therapeutics 4 (22%)
- Medical 3 (17%)
Stage
- Series A 6 (33%)
- Series B 6 (33%)
- Venture - Series Unknown 2 (11%)
- Pre-Seed 1 (6%)
- Series D 1 (6%)
Country
- Canada 13 (72%)
- United States 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Amine Benmoussa
Principal
|
Principal | Total investments: 2 | Find email | |
Dion Madsen
Senior Managing Partner
|
Senior Managing Partner | Total investments: 13 | Find email | |
Allyson Tighe
Analyst, Healthcare Venture Fund
|
Analyst, Healthcare Venture Fund | Total investments: 1 | Find email | |
Bharat Srinivasa
Analyst, Healthcare Venture Fund
|
Analyst, Healthcare Venture Fund | Total investments: 5 | Find email | |
Ela Borenstein
Managing Partner
|
Managing Partner | Total investments: 7 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Meissner leverages artificial intelligence to discover and develop next-generation superconducting materials. | $2.6M / Pre-Seed / Sep 01, 2026 | ||
| The PHEMI Trustworthy Health DataLab is a unique, cloud-based, integrated big data management system that allows healthcare organizations to enhance innovation and generate value from healthcare data by simplifying the ingestion and de-identification of data with NSA/military-grade governance, privacy, and security built-in.Conventionalproducts simply lock down data, PHEMI goes further, solving privacy and security challenges and addressing the urgent need to secure, govern, curate, and control access to privacy-sensitive personal healthcare information (PHI). This improves data sharing and collaboration inside and outside of an enterprise—without compromising the privacy of sensitive information or increasing administrative burden.Built on privacy-by-design principles, the software gives researchers, scientists, and clinicians faster access to more information while ensuring that they only see data on a need-to-know basis. Responsible data sharing and a governance framework facilitate compliance with privacy regulations.PHEMI Trustworthy Health DataLab can scale to any size of organization, is easy to deploy and manage, connects to hundreds of data sources, and integrates with popular data science and business analysis tools.For more information, visit https://www.phemi.com/ and follow us on Twitter @PHEMISystems, Linkedin, Youtube, and Facebook | $10M / Series B / Jun 27, 2017 | ||
| Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells. The company's drugs combine a proprietary high throughput gene-editing and target discovery method with high-resolution protein crystallography, computational biology and clinical informatics, enabling patients to improve cancertreatment both with single therapy and in combination with existing drugs and treatments. | $68M / Series A / Jun 22, 2017 | ||
| Clearwater Clinical designs and manufactures innovative, affordable, medical-grade devices that apply the advantages of mobile technology to common clinical practices. | $6M / Series A / Jan 12, 2017 | ||
| Imagia's mission is to leverage advances in artificial intelligence and accelerate the advent of accessible personalized medicine.The company's platform leverage advances in artificial intelligence to provide outcome-based structured clinical data and federated learning capabilities across multiple sources while preserving privacy,enabling clinicians to drive end-to-end discoveries of predictive, diagnostic, and prescriptive analytics. | $4.2M / Series A / Dec 13, 2016 | ||
| The PHEMI Trustworthy Health DataLab is a unique, cloud-based, integrated big data management system that allows healthcare organizations to enhance innovation and generate value from healthcare data by simplifying the ingestion and de-identification of data with NSA/military-grade governance, privacy, and security built-in.Conventionalproducts simply lock down data, PHEMI goes further, solving privacy and security challenges and addressing the urgent need to secure, govern, curate, and control access to privacy-sensitive personal healthcare information (PHI). This improves data sharing and collaboration inside and outside of an enterprise—without compromising the privacy of sensitive information or increasing administrative burden.Built on privacy-by-design principles, the software gives researchers, scientists, and clinicians faster access to more information while ensuring that they only see data on a need-to-know basis. Responsible data sharing and a governance framework facilitate compliance with privacy regulations.PHEMI Trustworthy Health DataLab can scale to any size of organization, is easy to deploy and manage, connects to hundreds of data sources, and integrates with popular data science and business analysis tools.For more information, visit https://www.phemi.com/ and follow us on Twitter @PHEMISystems, Linkedin, Youtube, and Facebook | $9.3M / Series A / Aug 11, 2015 | ||
| Xagenic Inc., a Toronto, Canada-based molecular diagnostics company developing new technology for decentralized, rapid diagnostic testing, and a true point-of-care platform. Our aim is to enable on-demand, near-patient molecular testing, empowering clinicians in making treatment decisions for their patients at the time of the first consultation.This will dramatically improve patient care and reduce health care costs. Xagenic has adapted this technology to permit rapid, enzyme-free detection of nucleic acids from clinical samples.We are commercializing a simple and fully automated technology platform that will enable widespread decentralized diagnostic testing to be performed outside of clinical laboratories. Our team is developing infectious disease tests that will allow the detection of a variety of analytes in situations where rapid test turnaround will provide clinically actionable results. | $11.8M / Series B / Jul 09, 2015 | ||
| Clementia is a clinical-stage company innovating treatments for people with ultra-rare bone disorders. The company develops disease-modifying treatments for patients suffering from debilitating bone and other diseases with a high unmet medical need. The company's lead product candidate, palovarotene, is an oral small molecule that has shownpotent activity in preventing abnormal new bone formation as well as fibrosis in a variety of tissues.Clementia Pharmaceuticals was founded in 2012 and is headquartered in Montréal, Quebec. | $60M / Venture - Series Unknown / Jun 23, 2015 | ||
| Milestone Pharmaceuticals is a drug development company developing novel small molecule therapeutics based on clinically validated mechanisms for cardiovascular diseases. Milestone's lead product is a novel and potent short-acting calcium channel antagonist for the systemic treatment of transient cardiovascular conditions such as atrialarrhythmias and angina. | $17M / Series B / Jun 15, 2015 | ||
| The Profound Medical team is committed to creating the powerful combination of real-time MR-guidance as the imaging platform and ultrasound as the energy source for delivering non-invasive ablative tools to clinicians. These key technology pillars, linked with intelligent software and robotics, have the potential to fulfill unmet needs of patientsand clinicians in many anatomies and disease states, including prostate cancer, uterine fibroids, and bone metastases. Our mission is to profoundly change the standard of care by creating a tomorrow where clinicians can confidently ablate tissue with precision; a tomorrow where patients have access to safe and effective treatment options, so they can quickly return to their daily lives. | $23.2M / Venture - Series Unknown / Apr 30, 2015 | ||
| See all 18 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does BDC Healthcare Venture invest in?
BDC Healthcare Venture invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series A and Series B stage. Most of the 18 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is BDC Healthcare Venture's check size?
BDC Healthcare Venture typically joins rounds of $4.2M–$68M at Series A, $4.7M–$30M at Series B and $23M–$60M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds BDC Healthcare Venture participates in.
How do I contact BDC Healthcare Venture?
Public channels for BDC Healthcare Venture include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at BDC Healthcare Venture?
The team at BDC Healthcare Venture includes Amine Benmoussa (Principal), Dion Madsen (Senior Managing Partner) and Allyson Tighe (Analyst, Healthcare Venture Fund), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
